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Background: Post transplant relapse remains a main cause
of transplant failure and mortality in patients with myelo-
dysplastic syndrome (MDS) and acute myelogenous
leukemia (AML). Azacitidine, a hypomethylating agent, has
been reported to reduce post transplant relapse in these
patients after unmodiﬁed allogeneic hematopoietic stem cell
transplantation (HSCT). There have been no reports of aza-
citidine use in patients undergoing T cell depleted (TCD)
HSCT.
Patients: Nine patients; 4 with high risk MDS, 1 with AML
evolved from MDS, 2 with therapy-related AML, and 2 with
de-novo AML, who had undergone TCD HSCT, were treated
with azacitidine post transplant. The dose of azacitidine, as
determined in a phase 1 study, was 32mg/m2 subcutane-
ously daily for 5 days monthly. All patients had been condi-
tioned with a myeloablative regimen of busulphan,
melphalan, ﬂudarabine and rabbit ATG and had received
a peripheral blood stem cell graft from a matched or mis-
matched related or unrelated donor.
Results: Seven patients were treated in complete remis-
sion as a prophylactic measure, one patient was treated in
relapse and one patient received, in addition to azaciti-
dine, a dose of DLI (0.5x106 CD3 cells/kg) for increasing
host chimerism and a new cytogenetic abnormality.
Treatment began at a median of 117 days post transplant
(range 80-333) and patients received a median of 3 cycles
(range 1-7). At a median of 8 months follow-up, 7 patients
were alive and 2 had died; one of pulmonary failure,
possibly secondary to busulphan and the other patient of
relapsed disease. In one patient, treatment was dis-
continued after development of an EBV-LPD while
receiving budesonide for upper GI GvHD, and in another
patient therapy was discontinued because of severe
pancytopenia secondary to adenovirus infection. A third
patient had treatment interruption after developing
dyspnea secondary to heart failure and chronic obstructive
lung disease. The patient with relapsed disease had
persistent pancytopenia throughout the treatment. In the
8 remaining patients, there were 4 with grade I anemia
and/or thrombocytopenia. Only one of the 8 patients
required G-CSF and azacitidine dose reduction (20%).
However, this patient's neutrophils were noted to decrease
prior to initiation of Azacitidine, possibly related to
treatment of an EBV-LPD with Rituxan. Two patients had
grade I skin GvHD and one patient had grade 1 upper GI
GvHD. Therapy with azacitidine did not worsen the
severity of GvHD.
Conclusions: This review shows that timely administration
of low dose azacitidine is feasible after TCD transplant in
patients with MDS and AML. The most common toxicity
related to azacitidine, myelosuppression, has been reported
only in patients who had concomitant viral infections. A
phase II trial will be conducted to assess the efﬁcacy of post
transplant azacitidine after TCD transplant.401
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Background: We have previously shown that lymphocyte
and monocyte recovery by 2-3 months post-allogeneic
hematopoietic (HCT) is associated with improved survival
in recipients of both myeloablative and reduced intensity
conditioning. Here, we test the hypothesis that the allo-
graft lymphocyte and monocyte content correlates with
recovery of those hematologic parameters prior to and at
day +100.
Methods: We pooled the hematologic recovery data,
including absolute lymphocyte and monocyte counts (ALC
and AMC, respectively) at day +15, +30, +60, and +100, and
outcomes data from our original cohorts of allogeneic HCT
recipients undergoing myeloablative or reduced intensity
(ﬂudarabine/melphalan). We included only those with
peripheral blood stem cell allografts and excluded thosewith
incomplete data regarding allograft leukocyte subset
content. 216 consecutive patients from 2000-2010 were
included in the analysis.
Results: Neither allograft lymphocyte, monocyte, gran-
ulocyte, nor CD34+ content correlated with hematologic
recovery parameters or overall survival in this cohort when
cell doses were analyzed as continuous variables or divided
in quartiles. No overall prognostic or optimal pattern of
allograft cellular content as determined by unsupervised
hierarchical clustering could be identiﬁed. With this pooled
data, prognostic factors for overall survival based on multi-
variate analysis included severity of chronic GVHD (P< .001),
development of post-transplant relapse (P ¼ .001), day +60
AMC > 0.3 x 109 cells/L (P ¼ .0015), and day +100 ALC > 0.3 x
109 cells/L (P < .001).
Conclusions: We conclude that, unlike in the autologous
HCT setting, post-allogeneic HCT lymphopenia and mono-
cytopenia appear to be related to complications and treat-
ment-related factors, and not related to allograft leukocyte
content.402
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Relapse remains a major problem after allogeneic stem
cell transplant (alloHSCT). There are limited data on the
outcomes after second alloHSCT. We conducted a single
institution retrospective review of 39 subjects who have
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survival analyses (Kaplan Meier log-rank test) were con-
ducted to investigate factors affecting disease-free survival
(DFS) and overall survival (OS). Group differences between
cases with/without GVHD were examined by t-tests on
engraftment lab variables.
The median age was 44 years (20-70). AML/MDS
accounted for 71% of the cases. Indications for second
alloHSCT were graft failure (16%) and disease relapse
(84%). Myeloablative conditioning was used in 62% of
the patients. Median time from ﬁrst to second trans-
plant was 427 days (49-3835) and median time from
relapse to second alloHSCT was 142 days (16-2524). 62%
of the second alloHSCTs were from an unrelated donor.
36% of second transplants were from the original donor.
OS at 1 and 5 years was 41% and 21% respectively
[median 229 days (5 e 5320)]. Factors prolonging OS
were: GVHD (P ¼ .05), chronic GVHD (cGVHD) (P < .01)
and using the same donor for both alloHSCTs (P < .01).
Male recipients, transplant from females to males, and
transplants from unrelated donors trended towards
better survival rates but were not signiﬁcant (P ¼ .069,
0.09, and 0.059 respectively). Survival was not affected
by: age, acute GVHD (aGVHD), diagnosis, risk stratiﬁca-
tion at diagnosis or second alloHSCT, remission status at
second alloHSCT, conditioning intensity, HLA compati-
bility, donor's sex, or CMV status of the donor/recipient.
The median DFS after the second alloHSCT was 112 days
(5-4759). Incidence of aGVHD and cGVHD was 41% and
41% respectively. Patients who developed GVHD or
cGVHD had better DFS (P < .01, P ¼ .03, respectively).
Risk of GVHD was higher in patients who received more
CD34/kg cells (P ¼ .02) while CD3/kg dose was not
statistically signiﬁcant. Remission status at the time of
the second alloHSCT did not affect OS or DFS. 13% of the
patients developed CMV viremia. Median time to
neutrophil engraftment was 12 days (4-37), and median
platelet engraftment >50,000/mcL was 21 days (9-103).
Patients who developed GVHD had earlier platelet
engraftment (Means: 16 vs. 30 days, P ¼ .04).
This single center experience of second alloHSCT suggests
this treatment results in long-term survival in select patients.
Survival is improved when the original donor is used as the
second donor. Future studies will focus on predictive
modeling to help choose patients who may beneﬁt most
from a second alloHSCT.403
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Graft failure is a well described complication of allogeneic
hematopoietic cell transplantation (HCT). The likelihood of
graft failure is greater when an HLA-mismatched donor
(such as umbilical cord blood or haploidentical donor) is
utilized. Salvage transplantations are associated with high
mortality because of common concurrent infections and
poor tolerance to reconditioning. We describe the use of
a novel reduced-intensity regimen that combines four potent
immunosuppressive but well tolerated agents with non-
overlapping toxicities.
Patients received 8 Gy TLI divided 2 Gy per fraction (once
daily on days -10, -9, and twice daily on day -8). Fludarabine
at 40mg/m2/day on the following 3 days (-7, -6, and -5).
Cyclophosphamide at 50mg/kg/day over 3 days (-4, -3, -2).
Rabbit ATG at 1mg/kg on day -3, and then 3mg/kg/day on
days -2 and -1. Patients then received a CliniMacs T-cell
depleted peripheral blood stem cell graft from a hap-
loidentical donor. The patients were typically heavily pre-
treated, had prolonged neutropenia, andmany had identiﬁed
infections.
In total, 7 patients experienced graft failure after hap-
loidentical donor HCT (3 had primary graft failure; 4 had
brief engraftment with subsequent rejection). They received
salvage HCT at a median of 37 days (range 31 e 78 days)
following the ﬁrst HCT (with the same haploidentical donor
in 5 and an alternative haploidentical donor in 2 recipients).
Patient 7 required modiﬁcation of the regimen (no cyclo-
phosphamide given) due to ongoing mechanical ventilation
and pressor support. Six of the 7 patients (86%) experienced
durable engraftment beginning at amedian of 12 days (range
10 e 27 days). All 6 were successfully discharged from the
hospital post-engraftment including Patient 7. The remain-
ing patient had rapidly progressive disease and never had
signs of engraftment before death at day 101 after the salvage
HCT. No other patient has relapsed. Patient 7 ultimately
expired due to CMV pneumonitis at 103 days after salvage
HCT. The remaining ﬁve patients are alive at a median of 846
days after salvage HCT (range 131 to 2569 days). Two patients
had acute and 3 had chronic GvHD; all resolved.
Our results indicate that this novel immunosuppressive
regimen is tolerable and effective in this heavily pretreated
patient population. High success rate in reengraftment was
observed despite the use of T-cell depleted haploidentical
grafts, including those from the same donor whose graft was
previously rejected.ays) 2nd Donor Time to Neutrophil Engraftment (days) Outcome
Mother 27 Alive
Mother 11 Alive




Father 13 Expired (CMV)
